.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Chinese Patent Office
Cerilliant
Citi
Federal Trade Commission
Johnson and Johnson
Deloitte
Farmers Insurance
Express Scripts
Fuji

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018248

« Back to Dashboard

NDA 018248 describes OXYTOCIN, which is a drug marketed by Fresenius Kabi Usa, Hikma Farmaceutica, Teva Pharms Usa, West-ward Pharms Int, and Abbott, and is included in five NDAs. It is available from five suppliers. Additional details are available on the OXYTOCIN profile page.

The generic ingredient in OXYTOCIN is oxytocin. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the oxytocin profile page.

Summary for 018248

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 018248

Medical Subject Heading (MeSH) Categories for 018248

Suppliers and Packaging for NDA: 018248

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OXYTOCIN oxytocin INJECTABLE;INJECTION 018248 NDA Cardinal Health 55154-9356 55154-9356-5 5 VIAL in 1 BAG (55154-9356-5) > 1 mL in 1 VIAL
OXYTOCIN oxytocin INJECTABLE;INJECTION 018248 NDA Cardinal Health 55154-9577 55154-9577-5 5 VIAL in 1 BAG (55154-9577-5) > 1 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength10USP UNITS/ML (10USP UNITS/ML)
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength100USP UNITS/10ML (10USP UNITS/ML)
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength300USP UNITS/30ML (10USP UNITS/ML)
Approval Date:Jul 27, 2007TE:RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Cantor Fitzgerald
Farmers Insurance
McKinsey
Moodys
Healthtrust
Medtronic
US Department of Justice
Novartis
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot